Granules India has reported results for third quarter ended December 31, 2013.
The company has reported over four fold jump in its net profit at Rs 22.99 crore for the quarter as compared to Rs 5.43 crore for the same quarter in the previous year. Total income from operations of the company has increased by 50.68% at Rs 262.12 crore for quarter under review as compared to Rs 173.96 crore for the quarter ended December 31, 2012.
On the consolidated basis, the group has reported around four fold jump in its net profit at Rs 21.81 crore for the quarter ended December 31, 2013 as compared to Rs 5.81 crore for the same quarter in the previous year. Total income from operations of the group has increased by 45.50% at Rs 284.05 crore for quarter under review as compared to Rs 195.22 crore for the quarter ended December 31, 2012.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: